OBJECTIVES: Single-port video-assisted thoracoscopic surgery (SPVATS) anatomical resection has been shown to be a feasible technique for lung cancer patients. Whether SPVATS has equivalent or better oncological outcomes for lung cancer patients remains controversial. The purpose of this study was to evaluate the perioperative and mid-term survival outcomes of SPVATS in 2 different medical centres.
Mid-term survival outcome of single-port video-assisted thoracoscopic anatomical lung resection: a two-centre experience 
INTRODUCTION
Lung cancer is the leading cause of cancer-related death all over the world. Surgery is the treatment of choice for patients with early-stage non-small-cell lung cancer (NSCLC) and selected Stage IIIA patients [1] [2] [3] . Roviaro et al. [4] first described video-assisted thoracoscopic surgery (VATS) lobectomy in 1992. Thereafter, VATS mushroomed rapidly and has spread all over the world. Over the last 2 decades, minimally invasive thoracoscopic anatomical lung resection with lymph node dissection has become widely accepted as a safe and sound oncological treatment option [5, 6] . The evolution of minimally invasive VATS has driven the development of sophisticated instruments and varied concepts to cope with the demands of working through smaller and fewer incision wounds. Single-port video-assisted thoracoscopic surgery (SPVATS) is now being used for an ever-growing number of applications [7] [8] [9] [10] [11] , even including major lung resection for lung cancer [7] . However, the majority of the single-port VATS-related studies are only related to its perioperative outcomes and feasibility. There are, as yet, few studies reporting its oncological results [9] [10] [11] . The objective of this study was not only to evaluate the perioperative outcomes but also to discuss the mid-term oncological outcome, as observed through our experience from 2 medical centres.
MATERIALS AND METHODS

Patients
A retrospective observation study was performed in patients undergoing an SPVATS for major pulmonary resections in the Minimally Invasive Thoracic Surgery Unit at Coruña Hospital A total of 442 patients received SPVATS, but 78 patients were excluded from this study due to secondary lung cancer or benign lung lesion, and a further 57 patients who received neoadjuvant therapy were also excluded. Finally, a total of 307 patients were enrolled in this study. The preoperative workup included chest radiography, bronchoscope, spirometry, chest tomography and a detailed search for distant metastasis, using positron emission tomography and brain images. Bone scan was used optionally for patients with suspected bone metastasis. All enrolled patients had clinical nodal staging with positron emission tomography. Clinical cT 1-2 N0 patients without mediastinal lymph node emission did not undergo an invasive mediastinal procedure, such as mediastinal scope or endobronchial ultrasound fine-needle aspiration. A selective mediastinoscopy or endobronchial ultrasound fine-needle aspiration was performed on patients with either positron emission tomography-positive mediastinal lymph node or when the multidisciplinary team had recommended exclusion of multiple N2 station metastasis disease. Clinical records of each patient were reviewed for demographic and clinical data including age, gender, body mass index, smoking status, preoperative pulmonary function, Eastern Cooperative Oncology Group (ECOG) performance status, associated comorbidities and clinical stage. In addition, records were reviewed for perioperative and pathological data, including surgical approach, 30-day operative mortality (defined as death during the same hospitalization or within 30 days after the operation), 90-day morbidity and mortality (defined as death within 90 days after surgery), duration of drainage, length of postoperative hospital stay, tumour size, histology, lymph node dissection numbers and pathological stage.
Surgical techniques
The surgical technique is the same as that described in previous articles [7, 9] . The surgeon and the assistant were both in front of the patient in order to have the same thoracoscopic view. An incision was made in the 5th intercostal space, and without rib spreading, vision was obtained through a 30 thoracoscope and instruments with proximal and distal articulation were used to perform the procedure. Vessels were divided using endostaple or vascular clips if the angle was not favourable for endostapler. Resected lung specimen was retrieved through a plastic retrieving bag. Sometimes the incision wound was enlarged to retrieve the specimen completely with the whole plastic retrieving bag, especially for those patients with tumours >5 cm. The eligibility criteria for SPVATS segmentectomy included ground-glass opacity lesion <2 cm without clinical evidence of hilar or mediastinal lymph node metastasis. During the operation, we sent segmental or hilar lymph node samples for intraoperative frozen examination. If lymph node metastasis was highly suspected, such as fixed or enlarged lymph node, we shifted the operation method to lobectomy. In general, the choice of lobectomy, bilobectomy or pneumonectomy depended on the size and location of the tumour. Systemic lymph node dissection was performed for all patients. Postoperative complications were all gathered and classified in a scale from I to V according to the Clavien-Dindo classification [12] . Grades I and II represented minor complications requiring no therapy or pharmacological intervention. Grades III and IV represented major complications requiring surgical intervention or life support. Grade V complications implied death. If a patient had multiple concurrent complications, only the most severe complication was considered. Details are given in Table 1 .
Follow-up
Patients returned to the outpatient clinics every 3 months for 2 years and then every 6 months annually up to 5 years. Upon each visit, a chest plain film was taken. If chest plain film revealed abnormal findings, restaging examination and biopsy would be arranged sequentially. Otherwise, chest tomography would be arranged annually for each patient if there was no abnormal finding on annual surveillance. The date of recurrence was defined as the date of positive findings on imaging.
Statistics
All collected clinicopathological factors were analysed by SPSS (version 19, Chicago, IL, USA). Overall survival (OS) was defined as the time from surgery until death from any cause, while patients who did not die during the study period were censored at the date of the last available follow-up. Disease-free survival (DFS) was defined as the time from surgery until disease relapse during the study period. If disease did not recur during the study period, patients were censored at the date of the last follow-up.
DFS and OS were estimated using the Kaplan-Meier method. The log-rank test was used to determine significance of survival distributions. A P-value <0.05 was considered statistically significant. 
RESULTS
Perioperative outcomes
Between January 2014 and February 2017, 307 patients, comprising 215 men (70%) and 92 women (30%), underwent SPVATS anatomical resection for NSCLC (CHUAC: 234, CGMH: 73). Segmentectomy was used in 23 patients, lobectomy was used in 263 patients, bilobectomy was used in 12 patients and pneumonectomy was used in 9 patients. The clinical and demographic characteristics of the patients are presented in Table 2 . Mean operation room time for the single-port major lung resection was 201.69 ± 61.32 min. Regarding mediastinal lymphadenectomy, the mean number of resected N1 and N2 lymph nodes was 5.74 ± 3.12 and 9.02 ± 5.32, respectively ( Table 2 ). Conversion was necessary in 8 (2.6%) cases. Open thoracotomy was undertaken in 6 cases because of vascular injury or dense adhesion around the mediastinal surface. Two cases were converted to 2-port VATS to shorten the operative time (Table 3) . Mean drainage days and postoperative hospital stay were 3.90 ± 2.98 and 5.03 ± 3.34 days, respectively. The overall 30-day mortality, 90-day morbidity and mortality rate was 0.7%, 20.1% and 0.7%, respectively.
Mid-term disease-free survival and overall survival outcome
The majority of the cases were subtypes of adenocarcinoma (59.6% Fig. 1A -D, and the details for the AJCC 7th and AJCC 8th DFS and OS Stage 1 are shown in Fig. 2A and B (Supplementary Material, File S2).
DISCUSSION
Numerous reports from high-volume centres have shown that SPVATS anatomical resection can be a feasible and safe alternative compared with traditional VATS anatomical resection with regard to short-term outcomes with potential benefits that include similar lymph node dissection numbers [13] [14] [15] [16] , specific and effective postoperative pain control [17] , decreased acute postoperative pain, shorter length of chest tube duration and hospital stay [14] [15] [16] . As for chest tube duration and postoperative hospital stay, our current 2-centre experience was consistent with the above-mentioned reports [14] [15] [16] . When it came to postoperative morbidity and in-hospital mortality rates, our cohort showed that SPVATS has acceptable in-hospital mortality and complication rates compared to the operative approach (Table 4) . Although the postoperative complication rate was 20.1%, the majority of the complications were minor complications, including prolonged air leakage, arrhythmia and so on. In a comparative study of lung cancer patients who received VATS or thoracotomy, Boffa et al. [18] found that the postoperative complication rate of the VATS group was 30% in their series, which is better than the thoracotomy group in clinical Stage I lung cancer. Furthermore, in a national database analysis matching thoracotomy, VATS and robotic-assisted thoracoscopic surgery (RATS), postoperative complication rates were 54.1%, 45.3% and 43.8%, respectively. Thus, our complication rate was acceptable compared with other operative approaches [19] . Major complications occurred in 8 (2.6%) patients. One of the deceased patients was an HIV carrier and developed thrombocytopenia. He had no choice but to receive the operation after discussion with the cancer committee. After the operation, he died due to severe sepsis and thrombocytopenia. The other deceased patient had received previous thoracic surgery and developed pulmonary hypertension on the 7th day after SPVATS lobectomy. He died due to multiple-organ failure. The rate of conversion to multiport VATS or open thoracotomy was consistent with the reported largest series of multiport VATS, RATS [20] [21] [22] [23] [24] , where the conversion rate varied from 2.5% to 10% (Table 4) . There were 16 patients with bleeding accidents during the operation, but only 4 catastrophic bleeding episodes required conversion to open surgery. Most of the bleeding episodes could be adequately managed through a single-port surgical technique as mentioned in our previous report [25] . In addition to our perioperative outcomes, our study had several unique aspects that previously published series seldom mentioned. First, since 2011, when the first experience of SPVATS lobectomy was published [7] , suspicion regarding its feasibility and doubts about its safety have gradually diminished with the mushrooming of published reports from all over the world. However, the most important aspect of the surgery is the oncological result. Limited by the state of the art of our time, SPVATS surgeons are always vigilant and prudent about the survival outcome for lung cancer patients, while adopting new procedures under the same principle of oncology. Previously, Xie et al. [10] and Ng et al. [11] published their series about survival outcomes in relatively homogenous patient populations. Here, we present a preliminary report on DFS and OS for NSCLC patients from 2 different centres. Even though patient demography and ethnicity were different for the 2 centres, there was no significant difference in OS between the 2 hospitals for the AJCC 7th and AJCC 8th Stage I patients (P = 0.089, P = 0.133, Supplementary Material, File S3). So we might believe that SPVATS anatomical resection as a treatment option provides a therapeutic effect that is in line with the current average 2-year survival results for early-stage lung cancer patients [26] [27] [28] . The OS and stage-specific 2-year survival are consistent with that of large series [26] [27] and external validation [27] [28] , whether or not it is under the definition of the AJCC 7th or AJCC 8th stage classification. For locally Continued advanced NSCLC patients (Stage II and III), our initial treatment result is worth looking into, in future. However, due to the relatively limited case numbers, further observation is warranted. Second, our study is based on a 2-centre, international experience with 1 centre in Spain and 1 in Taiwan using similar staging criteria, surgical techniques and postoperative follow-up protocol to evaluate perioperative and mid-term outcomes of these relatively new surgical techniques. All included patients were free from neoadjuvant therapy and had adequate pulmonary function reserve. In terms of surgical technique, all of the surgeons used the same techniques as previously described by Gonzalez et al. [7] . Each author performed systemic hilar and mediastinal lymph node dissection, however, despite using the same principle of lymph node dissection, lymph node harvesting numbers were quite different between the 2 centres (7.6 vs 13.5). Riquet et al. [29] found that the number of removed lymph nodes was normally distributed with high inter-individual variability. Moreover, our 2 patient cohorts were from different geographical areas and differed ethnically. A complete hilar and mediastinal lymphadenectomy is more important than harvesting numbers of lymph nodes.
Third, our study used a relatively large population of SPVATS anatomical resections reported to date. Although we previously published our experience of bleeding control techniques by SPVATS [25] , cohort evidence was lacking to prove its feasibility. Our report was the first to describe such experience in 2 different centres.
Limitations
However, some limitations should be taken into account when the results are considered. First, lack of sufficient case numbers and unified adjuvant regimen of locally advanced NSCLC patients made it difficult to arrive at a more solid conclusion about the therapeutic effect with regard to mid-term survival outcome, although our initial results were on par with the average survival rate. For example, in our limited numbers of Stage 2B patients by the AJCC 7th classification, the 2-year DFS was lower than in 3A patients, which might reflect the heterogeneity of our 2B patients. We further analysed the AJCC 7th Stage 2B patients in our cohort. Forty-six percent (9/15) of patients had a tumour >7 cm with costal pleural invasion. Two patients had a tumour >5 cm with hilar lymph node metastasis, and 4 other patients had mediastinal pleural invasion. Three patients could not tolerate postoperative radiotherapy and received adjuvant chemotherapy only. Jeon et al. [30] found the combined T 3 descriptors group had a poorer prognosis than those with T 3 centrally located lesion, poorer than patients without complete adjuvant therapy. This could partially explain why the 2-year DFS of our AJCC 7th 2B patients was inferior to 3A stage. In addition, adjuvant chemotherapy also plays an important role in DFS and OS of locally advanced patients. Cisplatin-based doublet adjuvant chemotherapy has been used for pathological Stage II and Stage III patients in Spain and Taiwan, except the AJCC 7th Stage IB (T2aN0M0) patients. However, lack of unified adjuvant regimen might have introduced bias into the survival analysis. Further evaluation is warranted. Second, between different centres, there inevitably exists some bias among patient characteristics and differences in surgeon technique and proficiency. Although there was no significant survival difference for early-stage lung cancer patients between the 2 centres (Supplementary Material, File S3), such retrospective study bias might have had an effect on mid-term survival outcome. We still need a longer observation time to validate the therapeutic role of SPVATS anatomical resection for lung cancer patients. Third, lack of comparative information on multiport VATS, RATS or thoracotomy anatomical resection makes SPVATS for NSCLC patients less persuasive. It would be very important for us to conduct further study to distinguish perioperative and survival outcomes among multiport VATS, RATS and thoracotomy surgery.
CONCLUSION
In summary, our study showed that SPVATS anatomical resection is a feasible and safe procedure with low in-hospital mortality and morbidity rate, and acceptable mid-term DFS and OS outcomes for early-stage NSCLC patients. For locally advanced stage NSCLC patients, we need more patients and more time to confirm its therapeutic role in future.
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